Cardiometabolic diseases (CMDs) and cognitive disorders, including cardiovascular diseases, type 2 diabetes, and Alzheimer’s disease, stand as prominent global causes of morbidity and mortality, imposing substantial burdens on individuals and society. Therefore, there is a critical need to identify early risk predictors and potential therapeutic targets to mitigate the impact of these diseases.
Body compositions, comprising adipose tissue, skeletal muscle, and bone, are recognized as the body’s primary metabolic organs. Previous findings from in vivo and in vitro experiments suggest that these body compositions can secrete various cytokines involved in disease development and organ cross-talk. However, the roles of different body compositions in the development of CMDs and cognitive disorders in humans remain largely unexplored due to the lack of data from large-scale population-level studies.
The project is set to span 36 months, utilizing high-quality data from the UK Biobank (UKB). Our aim is to identify features of body compositions that can effectively predict the development of CMDs and cognitive disorders. These insights may serve as early risk indicators, enabling the identification of individuals at a heightened risk for these diseases. Additionally, the study seeks to identify potential therapeutic targets for related diseases.
